Late Phase Studies are a major driving force behind the development of (new) medicines. They manage the associated risks and promote commercial opportunities. The main aim of Late Phase Studies resides in studying the effectiveness, safety and acceptability of medicines in the market. Eurotrials uses cutting edge and technologically innovative solutions to gather information and accompanying data about its projects.

With more than 350,000 individuals included in its studies, Eurotrials is able to meet the specific needs and requirements of an increasingly demanding area.  The existence/availability of Epidemiological data and Post-commercialisation Studies data are crucial in validating Scientific, Therapeutic, Economic and Healthcare Policy solutions.